Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study

Abstract

Methods 333 HIV-1-infected adults on 3TC-containing triple regimens with <200 copies/mL for at least 6 months had their NRTI backbone randomly switched to either ABC/3TC or TDF/FTC. Pre-planned results at 1 year have been already published [2]. Treatment failure (defined as virological failure, discontinuation of study therapy, withdrawal of consent, lost to follow-up, progression to AIDS, or death), virological failure (defined as confirmed plasma HIV-1 RNA >200 copies/mL), adverse events, and changes in CD4 cells, fasting plasma lipids, glomerular filtration rate (GFR) (CockcroftGault), and transaminases at 3 years were compared between arms.

Extracted Key Phrases

Cite this paper

@inproceedings{Martnez2010LongtermOO, title={Long-term outcomes of switching to fixed-dose abacavir/lamivudine (ABC/3TC) or tenofovir/emtricitabine (TDF/FTC): 3-year results of the BICOMBO study}, author={E. Mart{\'i}nez and J Arranz and Daniel Podzamczer and Montserrat Lonc{\'a} and Judit Sanz and Pedro Barragan and Hernando Knobel and Esteban Ribera and Felix Gutierrez and Sara Valero and Bonaventura Clotet and David Dalmau and F L{\'o}pez Segura and J R Arribas and P. Barrufet and Ignacio Santos and Antoni Mairata I Payeras and Elisa de Lazzari and Judith Pich and J Ma Gatell}, year={2010} }